Whereas the literature primarily attributes brolucizumab-associated vasculitis to an immune complex reaction mediated by anti-drug antibody (ADA) formation, this mechanism is likely to play only a minor role in IOI following aflibercept 8 mg [21]. The gene discussed is ADA; the disease is vasculitis.